Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease - Secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT)
Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease - Secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT)
复制标题
DOI：
10.1253/circj.66.1096
复制
发表时间：
2002-12-01
影响因子：
3.3
通讯作者：
Itakura, H
中科院分区：
文献类型：
--
作者：
Mabuchi, H;Kita, T;Itakura, H
高血压主要与冠心病（CHD）的进展有关，其治疗对于有CHD病史的患者至关重要。他汀类药物，如辛伐他汀，降脂剂，是众所周知的，他们的能力，使患者的血脂水平正常化。辛伐他汀的日本脂质干预试验研究是首次在日本高胆固醇血症患者中进行的血脂水平与CHD发生之间关系的全国性研究。在5，127例患者中，仅在入组时有记录的CHD病史，4，673例接受开放标签的辛伐他汀治疗，初始剂量为5- 10 mg/天，并监测6年。血清总胆固醇（TC）大于或等于240 mg/dl的患者发生冠状动脉事件的风险往往高于总胆固醇
Hyperlipidemia is primarily implicated in the progression of coronary heart disease (CHD) and its treatment is essential for patients with a history of CHD. Statins such as simvastatin, the lipid-lowering agents, are well-known for their ability to normalize patient's serum lipid levels. The Japan Lipid Intervention Trial study of simvastatin is the first nationwide investigation of the relationship between serum lipid levels and the development of CHD in Japanese patients with hypercholesterolemia. Of 5,127 patients, exclusively with a history of documented CHD at enrollment, 4,673 were treated with open-labeled simvastatin at an initial dose of 5-10mg/day and were monitored for 6 years. The risk of coronary events tended to be higher in patients with a serum total cholesterol (TC) greater than or equal to240 mg/dl compared with total cholesterol